Skip to main content

Alan Fletcher, Charles Blitzer

Premium
PerkinElmer announced this week that Alan Fletcher has joined the company as vice president of business development for its Life and Analytical Sciences business.
 
In this role, Fletcher will be responsible for growing the biodiscovery business by developing strategic partnerships and alliances in life sciences research, and by introducing new technologies for the GPCR, kinase, and biomarker drug target classes.
 
Prior to PerkinElmer, Fletcher held multiple positions in the science and discovery systems business units at GE Healthcare.
 

 
Znomics announced this week that Charles Blitzer has been named to its board of directors.
 
Prior to Znomics, Blitzer held a number of positions at Barbeau Pharma, Fulcrum Pharma, and MGI Pharma.
 
From 1989 to 1992, Blitzer was with Marion Merrill Dow, last serving as vice president of corporate development. At Marion Laboratories, from 1977 to 1989, he was vice president of licensing and business development; director of licensing; and general and patent counsel.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.